

## Development Pipeline - Products built on a heritage of innovation

At Elan Drug Technologies we have a robust pipeline incorporating our technologies at various stages of clinical development. The following is a list of these projects in active clinical development.

Licensee	Product	EDT Technology	Phase 1	Phase 2	Phase 3	Filed
Janssen (J&J)	Invega® Sustenna™	Nano	Approved US, Filed Europe			
Acorda Therapeutics	Ampyra™	OCR	Approved US, Filed Europe & Canada			
EDT Proprietary	Morphine - Europe	OCR				
EDT Proprietary	Megestrol NCD - Europe	Nano				
EDT Proprietary	Pain product	Nano				
Zogenix	ZX002	OCR				
Various <sup>(1,2,3,4)</sup>	8 products	Nano, OCR				

Our current pipeline spans a range of therapeutic classes, routes of administration and licensee profiles.

14 products are in clinical development with Invega® Sustenna™ approved by FDA in July 2009 and Filed in Europe December 2009

Ampyra™ approved on January 22nd, 2010 in US, filed in Europe and Canada, Q1 2010 by Biogen Idec.

In addition, we have a large number of projects at the preclinical or formulation development stage.

1. Improved existing product

2. New chemical entity, not yet on market in any form

3. "Broad Deal" NanoCrystal® technology in licensees

4. Nano/OCR combination technology

*Nano relates to our NanoCrystal® technology, OCR relates to our Oral Controlled Release Platform*